CVD Equipment Corporation (NYSE:CVV) CEO Leonard A. Rosenbaum sold 9,691 shares of the stock on the open market in a transaction dated Monday, December 22nd. The stock was sold at an average price of $15.02, for a total value of $145,558.82. Following the transaction, the chief executive officer now directly owns 838,070 shares in the company, valued at approximately $12,587,811. CVD Equipment Corporation (NASDAQ:CVV) in last trading activity advanced 5.06% to close at $14.94. Company weekly performance is 0.54% while its quarterly performance stands at 13.35%. CVD Equipment Corporation (NASDAQ:CVV) is -13.14% away from its 52 week high.
On 18 December Genworth Financial, Inc. (NYSE:GNW) said it will take until next year to release the results of its latest review into whether it has adequate reserves for long-term care insurance. On last trading day Genworth Financial, Inc. (NYSE:GNW) advanced 0.83% to close at $8.46. Its volatility for the week is 2.74% while volatility for the month is 3.88%. GNW’s sales growth for past 5 years was -1.10% and its EPS growth for past 5 years was 22.50%. Genworth Financial, Inc. (NYSE:GNW) monthly performance is -7.14%.
USG Corporation (NYSE:USG) has been given a “BB-” credit rating by analysts at Morningstar. The firm’s “BB-” rating suggests that the company is an above-average default risk. They also gave their stock a three star rating. On last trading day USG Corporation (NYSE:USG) advanced 1.07% to close at $28.22. Its volatility for the week is 1.92% while volatility for the month is 2.20%. USG’s sales growth for past 5 years was -5.00% and its EPS growth for past 5 years was 15.90%. USG Corporation (NYSE:USG) monthly performance is -2.99%.
On 17 December Sprint Corporation (NYSE:S) said that it has decided not to extend its long lasting sponsorship with NASCAR beyond 2016, as the carrier struggles to keep its wireless business afloat. On Monday shares of Sprint Corporation (NYSE:S) closed at $4.22. Company’s EPS growth for next 5 years is recorded as 5.00%.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Director Duane Nash sold 11,933 shares of the stock in a transaction that occurred on Friday, December 26th. The stock was sold at an average price of $11.23, for a total value of $134,007.59. Following the transaction, the director now directly owns 11,829 shares of the company’s stock, valued at approximately $132,840. On Monday shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) closed at $11.36.